☰

Manjula Nakka, Ph.D. - Publications

Affiliations: 
2002 University of Kentucky, Lexington, KY 
Area:
Biochemistry, Analytical Chemistry
Tree Info Similar researchers PubMed Report error

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Nakka M, Allen-Rhoades W, Li Y, Kelly AJ, Shen J, Taylor AM, Barkauskas DA, Yustein JT, Andrulis IL, Wunder JS, Gorlick R, Meltzer PS, Lau CC, Man TK. Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma. Oncotarget. 8: 96738-96752. PMID 29228567 DOI: 10.18632/Oncotarget.18236  0.336
2016 Li Y, Nakka M, Kelly AJ, Lau CC, Krailo M, Barkauskas DA, Hicks JM, Man TK. p27 is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma. Cancer Research. PMID 27197201 DOI: 10.1158/0008-5472.Can-15-3189  0.389
2016 Nakka M, Li Y, Kelly AJ, Lau CC, Krailo M, Barkauskas DA, Hicks J, Man T. Abstract 2445: Cytoplasmic mislocalization of p27 promotes metastasis and its autoantibody correlates with prognosis in osteosarcoma Cancer Research. 76: 2445-2445. DOI: 10.1158/1538-7445.Am2016-2445  0.393
2015 Flores RJ, Kelly AJ, Li Y, Nakka M, Lau CC, Hicks J, Man T. Abstract 5163: A high level of circulating CXCL10 at initial diagnosis is associated with poor prognosis of osteosarcoma patients Cancer Research. 75: 5163-5163. DOI: 10.1158/1538-7445.Am2015-5163  0.365
2015 Chen X, Li Y, Nakka M, Man TK. Abstract 1622: The AKT inhibitor reverses protein trafficking and inhibits tumor cell motility of p27-mislocalized osteosarcoma cells Cancer Research. 75: 1622-1622. DOI: 10.1158/1538-7445.Am2015-1622  0.311
2014 Krause WC, Shafi AA, Nakka M, Weigel NL. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. The International Journal of Biochemistry & Cell Biology. 54: 49-59. PMID 25008967 DOI: 10.1016/J.Biocel.2014.06.013  0.331
2014 Nakka M, Li Y, McGee C, Lau C, Man TK. Abstract 5228: Characterization of miR-21 as a potential circulating biomarker for osteosarcoma Cancer Research. 74: 5228-5228. DOI: 10.1158/1538-7445.Am2014-5228  0.381
2013 Nakka M, Agoulnik IU, Weigel NL. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. The International Journal of Biochemistry & Cell Biology. 45: 763-72. PMID 23270728 DOI: 10.1016/J.Biocel.2012.12.012  0.361
2008 Agoulnik IU, Bingman WE, Nakka M, Li W, Wang Q, Liu XS, Brown M, Weigel NL. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Molecular Endocrinology (Baltimore, Md.). 22: 2420-32. PMID 18787043 DOI: 10.1210/Me.2007-0481  0.379
2006 Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Research. 66: 10594-602. PMID 17079484 DOI: 10.1158/0008-5472.Can-06-1023  0.351
Show low-probability matches.